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Background: Prostate-specific antigen (PSA) is a widely used specific tumor marker for prostate cancer. We
experienced a case of metastatic prostate cancer that was difficult to detect by repeat prostate biopsy despite a
markedly elevated serum PSA level.
Case presentation: A 64-year-old man was referred to our hospital with lumbar back pain and an elevated serum
PSA level of 2036 ng/mL. Computed tomography, bone scintigraphy, and magnetic resonance imaging showed
systemic lymph node and osteoblastic bone metastases. Digital rectal examination revealed a small, soft prostate
without nodules. Ten-core transrectal prostate biopsy yielded negative results. Androgen deprivation therapy (ADT)
was started because of the patient’s severe symptoms. Twelve-core repeat transrectal prostate biopsy performed
2 months later, and transurethral resection biopsy performed 5 months later, both yielded negative results. The
patient refused further cancer screening because ADT effectively relieved his symptoms. His PSA level initially
decreased to 4.8 ng/mL, but he developed castration-resistant prostate cancer 7 months after starting ADT. He died
21 months after the initial prostate biopsy from disseminated intravascular coagulation.
Conclusion: CUP remains a considerable challenge in clinical oncology. Biopsies of metastatic lesions and
multimodal approaches were helpful in this case.
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The serum prostate-specific antigen (PSA) level is widely
used for prostate cancer screening [1]. As the PSA level
may also be elevated in patients with prostatic inflamma-
tion and benign prostatic hypertrophy, definitive diagnosis
of prostate cancer requires prostate biopsy. However, pros-
tate cancer is occasionally difficult to diagnose by prostate
biopsy, even in patients with markedly elevated PSA levels.
We report a case of metastatic prostate cancer in a patient
who underwent three biopsy procedures that all yielded
negative results.* Correspondence: cohyama@cc.hirosaki-u.ac.jp
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A 64-year-old man was referred to our hospital with lumbar
back pain and an elevated serum PSA level of 2036 ng/mL.
Computed tomography showed enlarged mediastinal, para-
aortic, and iliac lymph nodes (Figure 1A,B,C). Bone scintig-
raphy and magnetic resonance imaging showed osteoblastic
lumber spine metastases (Figure 2). Digital rectal examin-
ation revealed a small, soft prostate without nodules. The
estimated total weight of the prostate was 34 g. Be-
cause of the markedly elevated PSA level, we considered
that biopsies of the metastases were not essential. Ten-
core transrectal prostate biopsy yielded negative results
(Figure 3A). Because the patient was experiencing se-
vere fatigue and pain, we regarded treatment to be a
higher priority than histological diagnosis. We diagnosed
TxN1M1b prostate cancer based on the clinical findings,
and started androgen deprivation therapy (ADT) with aal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Computed tomography before and after treatment. Pre-treatment images showed enlarged mediastinal (A, arrows), para-aortic
(B, arrows), and iliac (C, arrows) lymph nodes. Images nine months after ADT showed a partial response of the mediastinal (D, arrows), para-aortic
(E, arrows), and iliac (F, arrows) lymph nodes.
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anti-androgen agent (bicalutamide), together with zoledro-
nic acid therapy. To obtain a definitive diagnosis, 12-core
repeat prostate biopsy was performed 2 months later and
transurethral resection biopsy was performed 5 months
later. The resected transurethral specimen weighed 5 g
(the estimated total weight of the prostate: 16 g), but did
not contain prostate cancer tissue (Figure 3B,C). The pa-
tient refused further prostate cancer screening because
ADT effectively relieved his symptoms. Nine months after
the initial prostate biopsy, his enlarged lymph nodes had
shrunk in size (Figure 1D,E,F) and his PSA level had de-
creased to 4.8 ng/mL. However, he did not attend his rou-
tine follow-up appointments and was noncompliant with
ADT, and developed castration-resistant prostate cancer
7 months after starting ADT. We administered five courses
of docetaxel-based chemotherapy, but his response was in-
adequate. The patient died 21 months after the initial pros-
tate biopsy from disseminated intravascular coagulation.
His family refused to allow an autopsy.T1WIA B
Figure 2 Bone scintigraphy (A) and magnetic resonance imaging (B, CDiscussion
Carcinoma of unknown primary (CUP) is an unusual
malignant condition in which metastases are documented
without the identification of the primary site, even after
intensive screening [2]. CUP accounts for 3–5% of all can-
cers [3]. Extensive work-up with specific pathology in-
vestigations (immunohistochemistry, electron microscopy,
molecular diagnosis) and modern imaging technology
(computed tomography [CT], magnetic resonance im-
aging [MRI], mammography, positron emission tomog-
raphy [PET] scan) have resulted in some improvements
in diagnosis; however, the primary site remains unknown
in most patients, even after autopsy. Therefore, it remains
a major problem in clinical oncology. CUP is considered
the seventh or eighth most common type of malignancy
and fourth most common cause of cancer-related death
[4]. In a meta-analysis of 12 postmortem studies, the pri-
mary tumor was identified in 644 (73%) of 884 patients.
The most common primary sites were the lung (27%),
pancreas (24%), liver or bile duct (8%), kidney or adrenalT2WIC
) showed osteoblastic lumbar spine metastases (arrows).
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Figure 3 Histopathological examination findings. The first 10-core (A) and second 12-core (B) transrectal prostate biopsies and the transurethral
resection biopsy (5 g) (C) showed benign prostatic hyperplasia. The estimated total weight of the prostate at the time of transurethral resection was
16 g. The 34βE12 anti-cytokeratin monoclonal antibody was positive in all specimens. Original magnification: ×40.
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stomach (6%) [5]. In patients with CUP with skeletal me-
tastases, the prostate was the second most common pri-
mary site. A recent review of CUP in the urogenital
system reported the frequency of CUP of the prostate to
be 4% [6].
The reason most such primary tumors cannot be de-
tected is unclear. Common hypotheses include spontan-
eous regression or immune-mediated destruction of the
primary tumor, and inherently small primary tumors
[2,4,7,8]. Therefore, the utility of traditional CT and MRI
in detecting small lesions and non-enhancing lesions in
normal-sized structures is limited. Relatively recent stud-
ies showed the clinical value of 18 F-fluoro-2-deoxyglucose
positron emission tomography/computed tomography
(18 F-FDG PET-CT) in detecting primary tumors in patients
with CUP [7,9]. Han et al. [9] reported that 18 F-FDG PET-
CT whole-body imaging correctly detected primary tumors
in 54 of 120 patients (42.5%). The sensitivity, specificity andTable 1 Reported patients with a high PSA level and prostate
Authors Age PSA Prostate b
1st 2nd
1 Sato, et al. 73 100 Transrectal (6)
2 Nakata, et al. 61 56.3 Transrectal (9) Transrecta
3 Ueda, et al. 80 259 Perineal (6) Perineal (
4 Wakatabe, et al. 80 400 Transrectal (8) Perineal (
5 Wakatabe, et al. 69 96 Transrectal (4) Perineal (
6 Makino, et al. 75 4222 Perineal (12) Perineal (
7 Shin, et al. 75 439 Transrectal (20) TURP
8 Fukumoto, et al. 66 88.1 Perineal (8) Perineal (
9 Present case 64 2036 Transrectal (10) Transrecta
TURP: transurethral resection of the prostate.accuracy of 18 F-FDG PET-CT in detecting primary tumor
sites were 91.5%, 85.2% and 88.3%, respectively.
Two opposite approaches have been adopted in CUP
diagnostic procedures: one strategy is a “shotgun modal-
ity,” consisting of multiple examinations aimed at identify-
ing the primary tumor; the other is a “nihilistic modality,”
which adopts palliative therapy for the metastatic disease.
Because overall survival is poor in patients with CUP
(median: 6–14 months) [10], a reasonable intermediate
diagnostic strategy consists of undertaking procedures
with specific targets and low cost/benefit ratios [6].
In the present case, according to the guidelines for the
management of CUP [3], osteoblastic bone metastases in
a patient with a markedly elevated PSA level suggests
metastatic PSA+ cancer, and hormone-based treatment
is recommended if the primary lesion is not detected
within 1 month. As a PSA level > 2000 ng/mL strongly
suggests prostate cancer, we started ADT before obtaining
a histological diagnosis. As expected, ADT was effective incancer not diagnosed by prostate biopsy
iopsy (core numbers) Biopsy of metastatic site
3rd 4th
Cervical lymph node




14) Perineal (15) Iliac bone
Ureter
10) Perineal (17) Transrectal (3) External iliac lymph nodes
l (12) TURP Not performed
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obtain a definitive diagnosis of prostate cancer by repeat
prostate biopsies including transurethral resection biopsy,
all biopsies yielded negative results. Because initial biop-
sies only detect 65–77% of prostate cancers, repeat biop-
sies are frequently performed [11,12]. Djavan et al.
reported prostate cancer detection rates for biopsies 1, 2,
3 and 4 to be 22%, 10%, 5% and 4%, respectively [11].
Roehl et al. reported prostate cancer detection rates from
biopsies were 29%, 17%, 14%, 11%, 9% and 7%, for biopsy
procedures 1–6, respectively [12]. These reports indicate
that nearly a quarter of prostate cancers eventually de-
tected in these screening studies were missed by the initial
biopsy, and four prostate biopsies are needed to detect
99% of prostate cancers. Therefore, repeat biopsies are
common for suspected prostate cancer. However, in the
present case, the repeat biopsies may not have markedly
increased the likelihood of definitive diagnosis because the
number of biopsy cores was small, the same transrectal
approach was used after the initial negative biopsy, and
transurethral resection biopsy after ADT had low possibil-
ity of total resection of the tissue including cancer. Biop-
sies of the periprostatic area or via the perineal approach
before ADT may have yielded a definitive diagnosis.
Only four cases of adenocarcinoma in ectopic prostate
tissue have been reported [13-16]. Over 80% of ectopic
prostate tissue is located in the prostatic urethra, and
the second most common site is the neck of the urinary
bladder [17]. In the present case, we visualized the en-
tire urethra at the time of transurethral resection biopsy,
but did not detect any ectopic nodules. The likelihood
of metastasis from cancer in ectopic prostate tissue
seems low.
To our knowledge, only nine cases of prostate cancer that
could not be detected by repeat prostate biopsy have been
reported (Table 1) [18-24]. Digital rectal examination re-
vealed a small, soft prostate in all cases. Seven of the cases
(88%) were diagnosed by biopsy of metastatic lesions, pri-
marily in the bones or lymph nodes. Definitive diagnosis in
such cases may depend on biopsy of a metastatic lesion.
However, according to various reports [2,4,6,25,26], the pri-
mary site becomes obvious in only 15–20% of live patients,
and 15–25% remain undefined even at postmortem exami-
nations. Thus, biopsies of metastatic sites may be helpful,
but do not always locate primary tumors [27].
Although the serum PSA level is widely used as a
marker for prostate cancer, PSA may also be expressed
by cancers of the colon, liver, pancreas, kidney, adrenal
gland, skin, mammary gland, ovary, and salivary glands
[28,29]. When repeat prostate biopsies are negative, the
possibility of other malignancies should be considered.
Multimodal approaches sometimes detect primary ma-
lignancies that are potentially responsive to treatment.
Nevertheless, CUP remains a diagnostic and therapeuticchallenge for both patients and physicians in spite of re-
cent laboratory and imaging advantages.
Conclusion
CUP remains a considerable challenge in clinical oncol-
ogy. Biopsies of metastatic lesions and multimodal ap-
proaches that included 18 F-FDG PET-CT were helpful
in this case.
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